None listed
Conditions
Interventions
Drug : The UDCA group received UDCA 100 mg three times a day for two months, and the non-administered group was observed for two months without intervention.
Sponsors
Ajou University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: The Rome IV criteria define FD as one of four symptoms (postprandial fullness, early satiation, epigastric pain, epigastric burning) that occurred at least six months before diagnosis and persisted for the last three months. In addition, examinations involving endoscopy should reveal no structural abnormalities to explain these symptoms.
Exclusion criteria
Exclusion criteria: Patients with FD were excluded from this study if they had a history of i) gastrointestinal ulcers or inflammatory bowel diseases such as Crohn's disease or ulcerative colitis; ii) gastrectomy or intestinal resection (except appendectomy); or iii) viral liver disease (types A, B, C), cirrhosis, or any cancers, as well as iv) blood tests whose serum aspartate aminotransferase (AST), alanine aminotransferase (ALT) or gamma-glutamyltransferase (GGT) levels were more than three times the normal range or whose serum creatinine levels were more than 1.5 times the normal range; v) chronic renal failure, congestive heart failure, and thyroid disease; vi) persistent alcohol consumption (at least four bottles of soju per week, i.e., at least 240g of alcohol per week); or vii) severe biliary obstruction.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The questionnaire about dyspepsia measured each patient’s Nepean dyspepsia index-K (NDI-K) and Small intestinal bacterial overgrowth prevalence. | — |
Secondary
| Measure | Time frame |
|---|---|
| Adverse events | — |
Countries
Korea, Republic of
Contacts
Public ContactKYUNAM KIM
Ajou University Hospital
Outcome results
None listed